We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+6.92%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$588M
AUM Growth
+$7.2M
Cap. Flow
-$2.16M
Cap. Flow %
-0.37%
Top 10 Hldgs %
36.51%
Holding
220
New
75
Increased
41
Reduced
27
Closed
76

Top Buys

1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.57M
2
UTHR icon
United Therapeutics
UTHR
+$8.62M
3
INCY icon
Incyte
INCY
+$7.79M
4
COGT icon
Cogent Biosciences
COGT
+$7.05M
5
VKTX icon
Viking Therapeutics
VKTX
+$6.05M

Top Sells

1
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.95M
2
TERN
Terns Pharmaceuticals
TERN
+$6.74M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$4.21M
4
BIOA
BioAge Labs
BIOA
+$4.07M
5
CORT icon
Corcept Therapeutics
CORT
+$3.27M

Sector Composition

1 Healthcare 38.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRMY icon
51
Harmony Biosciences
HRMY
$1.94B
$2.6M 0.44%
92,864
+85,364
+1,138% +$2.8M
NTLA icon
52
CALL
Intellia Therapeutics
NTLA
$1.66B
$2.56M 0.44%
200,000
-12,400
-6% -$158K
CAPR icon
53
Capricor Therapeutics
CAPR
$1.11B
$2.4M 0.41%
78,851
-79,224
-50% -$2.11M
EYPT icon
54
EyePoint Inc
EYPT
$1.09B
$2.3M 0.39%
+178,545
New +$2.67M
BCYC
55
Bicycle Therapeutics
BCYC
$292M
$2.21M 0.38%
+476,424
New +$2.72M
ALMS
56
CALL
Alumis Inc
ALMS
$3.47B
$2.2M 0.37%
+100,000
New +$2.5M
INDV icon
57
Indivior Pharmaceuticals
INDV
$4.8B
$2.18M 0.37%
71,376
+54,056
+312% +$1.79M
NVO
58
PUT
Novo Nordisk
NVO
$228B
$2.05M 0.35%
55,900
+2,800
+5% +$133K
CELC icon
59
CALL
Celcuity
CELC
$4.31B
$2.02M 0.34%
+17,700
New +$1.93M
CLYM
60
Climb Bio
CLYM
$720M
$1.96M 0.33%
+286,126
New +$1.65M
ANNX icon
61
CALL
Annexon
ANNX
$965M
$1.96M 0.33%
353,200
+44,100
+14% +$248K
IVA
62
Inventiva
IVA
$1.07B
$1.94M 0.33%
352,399
+18,148
+5% +$111K
STTK icon
63
Shattuck Labs
STTK
$675M
$1.89M 0.32%
+293,664
New +$1.39M
LQDA icon
64
PUT
Liquidia Corp
LQDA
$6.69B
$1.89M 0.32%
+50,000
New +$1.86M
TARS icon
65
Tarsus Pharmaceuticals
TARS
$2.52B
$1.82M 0.31%
+25,942
New +$1.81M
ALKS icon
66
Alkermes
ALKS
$8.66B
$1.77M 0.3%
+50,000
New +$1.55M
MGNX icon
67
MacroGenics
MGNX
$262M
$1.73M 0.3%
+600,000
New +$1.28M
VRTX icon
68
Vertex Pharmaceuticals
VRTX
$123B
$1.71M 0.29%
3,840
-6,160
-62% -$2.87M
VYGR icon
69
Voyager Therapeutics
VYGR
$184M
$1.64M 0.28%
+423,642
New +$1.67M
REPL icon
70
CALL
Replimune Group
REPL
$799M
$1.57M 0.27%
+205,500
New +$1.57M
CRVS icon
71
CALL
Corvus Pharmaceuticals
CRVS
$1.2B
$1.56M 0.26%
+106,300
New +$1.7M
CTMX icon
72
CALL
CytomX Therapeutics
CTMX
$798M
$1.49M 0.25%
+316,000
New +$1.6M
AVXL icon
73
CALL
Anavex Life Sciences
AVXL
$217M
$1.47M 0.25%
477,600
+337,000
+240% +$1.46M
PCVX icon
74
Vaxcyte
PCVX
$8.09B
$1.46M 0.25%
25,071
+2,099
+9% +$114K
RLMD icon
75
Relmada Therapeutics
RLMD
$573M
$1.4M 0.24%
200,842
-188,553
-48% -$892K
1 2
3
4 5

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
BCM
Blume Capital Management Berkeley, California $588M AUM 29.16% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
BMWS
Brady Martz Wealth Solutions Grand Forks, North Dakota $587M AUM 17.88% 1-Year Est. Return
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return

Diadema Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Diadema Partners held 220 positions worth $588M, up 1.2% from $581M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Diadema Partners's Q1 2026 filing shows 75 new, 41 increased, 27 reduced and 76 closed positions. Its largest new stake was Jazz Pharmaceuticals: 54,755 shares worth $10.4M. The largest sale was Regeneron Pharmaceuticals, an estimated $7.95M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 29% a quarter earlier.

  • Diadema Partners's largest Q1 2026 buy was Jazz Pharmaceuticals: 54,755 shares worth $10.4M.
  • Diadema Partners added most to United Therapeutics in Q1 2026, an estimated $8.62M increase.
  • Diadema Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $6.74M.
  • Diadema Partners fully exited Regeneron Pharmaceuticals in Q1 2026, selling an estimated $7.95M.
  • Diadema Partners's ten largest holdings make up 37% of its $588M portfolio in Q1 2026.
  • Diadema Partners opened 75 new positions and closed 76 in Q1 2026.
  • Diadema Partners's portfolio value rose 1.2% quarter-over-quarter to $588M.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.